Valuation: Exelixis, Inc.

Market Cap 13.33B 11.59B 10.79B 9.9B 18.7B 1,272B 18.99B 127B 49.89B 633B 50.06B 48.96B 2,124B P/E 2026 *
16.7x
P/E 2027 * 14.3x
Enterprise Value 12.51B 10.87B 10.12B 9.29B 17.55B 1,194B 17.82B 119B 46.83B 595B 46.98B 45.95B 1,994B EV / Sales 2026 *
4.82x
EV / Sales 2027 * 3.98x
Free-Float
98.18%
Yield 2026 *
-
Yield 2027 * -
1 week-5.09%
1 month-3.01%
3 months+21.85%
6 months+32.58%
Current year+21.45%
1 week 46.05
Extreme 46.05
49.7
1 month 46.05
Extreme 46.05
50.29
3 years 17.75
Extreme 17.75
50.29
5 years 13.88
Extreme 13.885
50.29
10 years 8.02
Extreme 8.017
50.29
Manager TitleAgeSince
Chief Executive Officer 65 2010-07-21
Director of Finance/CFO 58 2015-07-14
Chief Operating Officer 63 2016-01-31
Director TitleAgeSince
Director/Board Member 70 2004-01-31
Director/Board Member 82 2004-07-31
Chairman 77 1997-12-31
Change 5-day change 1-year change 3-year change Capi.($)
-4.92%+0.46%+42.27%+158.69% 14.07B
+2.35%+0.77%+29.92%+85.38% 55.23B
-0.21%-6.52%+42.39%+64.10% 53.75B
-2.44%-1.61%-17.69%-15.68% 23.48B
-2.85%-8.20%-6.26%+361.83% 22B
+2.49%-1.27%+15.99%-10.53% 19.78B
+0.79%-2.39%+26.99%-31.34% 17.44B
+0.58%-7.23%+24.50%+519.07% 14.66B
+3.41%-7.83%+161.76%+284.91% 13.02B
-3.06%-2.45%+439.00%+140.96% 12.3B
Average +0.12%-1.82%+75.89%+155.74% 25.74B
Weighted average by Cap. +0.33%-0.10%+51.38%+123.23%

Financials

2026 *2027 *
Net sales 2.6B 2.26B 2.1B 1.93B 3.64B 248B 3.7B 24.76B 9.72B 123B 9.75B 9.54B 414B 2.92B 2.54B 2.37B 2.17B 4.1B 279B 4.17B 27.9B 10.95B 139B 10.98B 10.74B 466B
Net income 812M 706M 657M 603M 1.14B 77.51B 1.16B 7.74B 3.04B 38.59B 3.05B 2.98B 129B 942M 819M 762M 700M 1.32B 89.94B 1.34B 8.99B 3.53B 44.78B 3.54B 3.46B 150B
Net Debt -819M -712M -663M -609M -1.15B -78.21B -1.17B -7.81B -3.07B -38.94B -3.08B -3.01B -131B -1.7B -1.47B -1.37B -1.26B -2.38B -162B -2.42B -16.18B -6.35B -80.63B -6.37B -6.23B -270B
Logo Exelixis, Inc.
Exelixis, Inc. is an oncology company. The Company has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. It is also advancing and evolving its product pipeline portfolio, including its lead investigational asset, zanzalintinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma, for previously treated hepatocellular carcinoma and for previously treated, radioactive iodine-refractory differentiated thyroid cancer, and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer. The Company's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved the treatment of hypertension in Japan.
Employees
-
Date Price Change
26-07-31 €46.13 -4.92%
26-07-30 €48.51 +0.47%
26-07-29 €48.29 -2.36%
26-07-28 €49.45 +0.74%
26-07-27 €49.09 +1.00%
Trader
Investor
Global
Quality
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
19
Last Close Price
53.03USD
Average target price
52.07USD
Spread / Average Target
-1.82%

Quarterly revenue - Rate of surprise